Premium
Lipo‐Poly(L‐histidine) Hybrid Materials with pH‐Sensitivity, Intracellular Delivery Efficiency, and Intrinsic Targetability to Cancer Cells
Author(s) -
Johnson Renjith P.,
Jeong YoungIl,
John Johnson V.,
Chung ChungWook,
Choi Seon Hee,
Song Song Yi,
Kang Dae Hwan,
Suh Hongsuk,
Kim Il
Publication year - 2014
Publication title -
macromolecular rapid communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.348
H-Index - 154
eISSN - 1521-3927
pISSN - 1022-1336
DOI - 10.1002/marc.201300892
Subject(s) - drug delivery , doxorubicin , micelle , internalization , chemistry , endosome , in vivo , intracellular , cancer cell , biophysics , biocompatible material , nanotechnology , vesicle , conjugated system , in vitro , materials science , cancer , biochemistry , biomedical engineering , membrane , cell , organic chemistry , chemotherapy , biology , medicine , aqueous solution , microbiology and biotechnology , genetics , polymer
Biocompatible lipo‐histidine hybrid materials conjugated with IR820 dye show pH‐sensitivity, efficient intracellular delivery of doxorubicin (Dox), and intrinsic targetability to cancer cells. These new materials form highly uniform Dox‐loaded nanosized vesicles via a self‐assembly process showing good stability under physiological conditions. The Dox‐loaded micelles are effective for suppressing MCF‐7 tumors, as demonstrated in vitro and in vivo . The combined mechanisms of the EPR effect, active internalization, endosomal‐triggered release, and drug escape from endosomes, and a long blood circulation time, clearly prove that the IR820 lipopeptide DDS is a safe theranostic agent for imaging‐guided cancer therapy.